Cancer vaccine therapy using genetically modified induced pluripotent stem cell-derived dendritic cells expressing the TAA gene.

我们从iPS细胞中培养出诱导多能干细胞衍生的树突状细胞DCs (iPSDCs)，并比较了iPSDCs与骨髓衍生的树突状细胞DCs （bmdc）的成熟能力以及iPSDCs向淋巴结迁移的能力。我们通过腺病毒将天然肿瘤抗原hgp100基因转导到dc中，用转基因dc免疫小鼠一次。研究结果表明，iPSDCs在成熟和迁移方面与BMDCs具有同等的能力。此外，在转基因ipsdc免疫小鼠中生成了hgp100特异性ctl。这些ctl对B16细胞表现出与BMDCs一样高的细胞毒性。此外，用转基因ipsdc接种疫苗获得的治疗效果与用bmdc接种疫苗一样高。我们的研究表明，在肿瘤相关抗原特异性治疗性抗肿瘤免疫方面，转基因ipsdc与BMDCs具有同等的能力。

We developed the induced pluripotent stem cell-derived dendritic cells DCs (iPSDCs) from iPS cells and examined the capacity for maturation of iPSDCs compared to that of bone marrow-derived DCs (BMDCs) in addition to the capacity for migration of iPSDCs to lymph nodes. We adenovirally transduced the hgp100 gene, natural tumor antigens, into DCs and immunized mice once with the genetically modified DCs. Our results showed that iPSDCs have an equal capacity to BMDCs in terms of maturation and migration. Furthermore, hgp100-specific CTLs were generated in mice immunized with genetically modified iPSDCs. These CTLs exhibited as high a level of cytotoxicity against B16 cells as BMDCs. Moreover, vaccination with the genetically modified iPSDCs achieved as high a level of therapeutic efficacy as vaccination with BMDCs. Our study clarified that genetically modified iPSDCs have an equal capacity to BMDCs in terms of tumor-associated antigen specific therapeutic antitumor immunity.